AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
nitrofurazone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| NO2 - derivatives | 1950 | 59-87-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.593 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.603 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 27.925 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 4.046 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 40.010 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 48.040 | % | High | 1 |
| herg | hERG pIC50 | 3.690 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.056 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.698 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 38.740 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GRK3,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 | 77 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK2,CDK4,CDK9,DDR1,DYRK1B,GRK2,GSK3A,GSK3B,IRAK1,JAK2,MAP2K3,MAP2K6,MAP3K14,MAP3K21,MAPK7,MARK4,PRKDC,SIK2,STK33,SYK,TEK,TTK,UHMK1,ULK1 | 30 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 3.155 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 7.031 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 58.720 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.738 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 34.260 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.119 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 95.930 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 42.740 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1004.616 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 4, 1945 | FDA | SHIRE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Joint dislocation | 255.20 | 52.01 | 130 | 14349 | 44452 | 90569516 |
| Seronegative arthritis | 246.25 | 52.01 | 97 | 14382 | 18137 | 90595831 |
| Prescribed underdose | 204.43 | 52.01 | 135 | 14344 | 74884 | 90539084 |
| Joint stiffness | 192.43 | 52.01 | 132 | 14347 | 77910 | 90536058 |
| Walking aid user | 181.51 | 52.01 | 96 | 14383 | 35410 | 90578558 |
| Wound infection | 179.10 | 52.01 | 143 | 14336 | 106259 | 90507709 |
| Retinitis | 171.56 | 52.01 | 95 | 14384 | 38363 | 90575605 |
| Lupus vulgaris | 170.62 | 52.01 | 100 | 14379 | 44959 | 90569009 |
| Laryngitis | 157.11 | 52.01 | 99 | 14380 | 50654 | 90563314 |
| Lupus-like syndrome | 155.53 | 52.01 | 97 | 14382 | 48749 | 90565219 |
| Visual impairment | 144.36 | 52.01 | 139 | 14340 | 132226 | 90481742 |
| Upper respiratory tract infection | 142.30 | 52.01 | 136 | 14343 | 128182 | 90485786 |
| Type 2 diabetes mellitus | 139.59 | 52.01 | 167 | 14312 | 203077 | 90410891 |
| Hypercholesterolaemia | 133.38 | 52.01 | 118 | 14361 | 100774 | 90513194 |
| Osteoporosis | 131.82 | 52.01 | 115 | 14364 | 96416 | 90517552 |
| Anti-cyclic citrullinated peptide antibody | 131.79 | 52.01 | 71 | 14408 | 27150 | 90586818 |
| Sciatica | 124.99 | 52.01 | 114 | 14365 | 101268 | 90512700 |
| Joint range of motion decreased | 121.40 | 52.01 | 128 | 14351 | 135515 | 90478453 |
| Spinal fusion surgery | 117.19 | 52.01 | 51 | 14428 | 12232 | 90601736 |
| Spondylitis | 116.45 | 52.01 | 53 | 14426 | 14125 | 90599843 |
| Road traffic accident | 115.38 | 52.01 | 112 | 14367 | 107514 | 90506454 |
| Hepatic cirrhosis | 110.61 | 52.01 | 87 | 14392 | 63166 | 90550802 |
| Adjustment disorder with depressed mood | 110.04 | 52.01 | 83 | 14396 | 56670 | 90557298 |
| Dislocation of vertebra | 108.84 | 52.01 | 82 | 14397 | 55886 | 90558082 |
| Foot deformity | 108.54 | 52.01 | 84 | 14395 | 59567 | 90554401 |
| Hip arthroplasty | 108.49 | 52.01 | 93 | 14386 | 76115 | 90537853 |
| Exostosis | 108.13 | 52.01 | 80 | 14399 | 53054 | 90560914 |
| Liver function test increased | 107.68 | 52.01 | 97 | 14382 | 84758 | 90529210 |
| Bone erosion | 106.04 | 52.01 | 79 | 14400 | 52942 | 90561026 |
| Drug ineffective | 105.59 | 52.01 | 45 | 14434 | 1384253 | 89229715 |
| Prescribed overdose | 101.65 | 52.01 | 100 | 14379 | 97525 | 90516443 |
| Osteoarthritis | 101.54 | 52.01 | 140 | 14339 | 195590 | 90418378 |
| Red blood cell sedimentation rate increased | 98.12 | 52.01 | 91 | 14388 | 82504 | 90531464 |
| Deep vein thrombosis postoperative | 93.90 | 52.01 | 83 | 14396 | 70726 | 90543242 |
| Disability | 93.51 | 52.01 | 66 | 14413 | 40679 | 90573289 |
| Lower limb fracture | 90.21 | 52.01 | 88 | 14391 | 84925 | 90529043 |
| Ear infection | 87.01 | 52.01 | 79 | 14400 | 69696 | 90544272 |
| Swollen joint count increased | 85.63 | 52.01 | 97 | 14382 | 111109 | 90502859 |
| Pulmonary fibrosis | 84.88 | 52.01 | 95 | 14384 | 107408 | 90506560 |
| Autoimmune disorder | 84.36 | 52.01 | 81 | 14398 | 76663 | 90537305 |
| Irritable bowel syndrome | 83.90 | 52.01 | 132 | 14347 | 207316 | 90406652 |
| Wheezing | 83.47 | 52.01 | 142 | 14337 | 237938 | 90376030 |
| Grip strength decreased | 78.60 | 52.01 | 85 | 14394 | 92491 | 90521477 |
| Knee arthroplasty | 73.48 | 52.01 | 78 | 14401 | 83104 | 90530864 |
| Fibromyalgia | 70.92 | 52.01 | 122 | 14357 | 206147 | 90407821 |
| Urticaria | 69.69 | 52.01 | 154 | 14325 | 312580 | 90301388 |
| Delirium | 68.66 | 52.01 | 84 | 14395 | 104275 | 90509693 |
| Oedema | 68.24 | 52.01 | 118 | 14361 | 200177 | 90413791 |
| Injury | 65.58 | 52.01 | 115 | 14364 | 197234 | 90416734 |
| Amnesia | 62.91 | 52.01 | 82 | 14397 | 108423 | 90505545 |
| Mobility decreased | 62.20 | 52.01 | 129 | 14350 | 250605 | 90363363 |
| Fall | 61.33 | 52.01 | 4 | 14475 | 481806 | 90132162 |
| Drug-induced liver injury | 59.90 | 52.01 | 73 | 14406 | 90245 | 90523723 |
| Wound | 59.53 | 52.01 | 142 | 14337 | 302838 | 90311130 |
| Psoriasis | 58.29 | 52.01 | 93 | 14386 | 147661 | 90466307 |
| Gait inability | 57.52 | 52.01 | 92 | 14387 | 146364 | 90467604 |
| Rheumatic fever | 57.17 | 52.01 | 94 | 14385 | 153027 | 90460941 |
| Tachycardia | 56.46 | 52.01 | 95 | 14384 | 157578 | 90456390 |
| Helicobacter infection | 55.41 | 52.01 | 116 | 14363 | 226734 | 90387234 |
| Liver injury | 54.86 | 52.01 | 98 | 14381 | 170469 | 90443499 |
| Rheumatoid factor positive | 54.41 | 52.01 | 98 | 14381 | 171552 | 90442416 |
| C-reactive protein increased | 54.26 | 52.01 | 101 | 14378 | 181288 | 90432680 |
| Hypoaesthesia | 54.07 | 52.01 | 140 | 14339 | 314070 | 90299898 |
| Breast cancer stage III | 52.37 | 52.01 | 66 | 14413 | 84381 | 90529587 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sleep disorder due to general medical condition, insomnia type | 54.63 | 36.37 | 38 | 3806 | 105605 | 110479850 |
| Sciatica | 51.94 | 36.37 | 35 | 3809 | 92364 | 110493091 |
| Type 2 diabetes mellitus | 48.85 | 36.37 | 44 | 3800 | 177188 | 110408267 |
| Fibromyalgia | 46.26 | 36.37 | 42 | 3802 | 170867 | 110414588 |
| Road traffic accident | 42.76 | 36.37 | 33 | 3811 | 107365 | 110478090 |
| Seronegative arthritis | 41.34 | 36.37 | 16 | 3828 | 13161 | 110572294 |
| Helicobacter infection | 38.42 | 36.37 | 39 | 3805 | 181838 | 110403617 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B05CA03 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS IRRIGATING SOLUTIONS Antiinfectives |
| ATC | D08AF01 | DERMATOLOGICALS ANTISEPTICS AND DISINFECTANTS ANTISEPTICS AND DISINFECTANTS Nitrofuran derivatives |
| ATC | D09AA03 | DERMATOLOGICALS MEDICATED DRESSINGS MEDICATED DRESSINGS Medicated dressings with antiinfectives |
| ATC | P01CC02 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS Nitrofuran derivatives |
| ATC | S01AX04 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Other antiinfectives |
| ATC | S02AA02 | SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
Related Drugs by ATC class:
B05CA Antiinfectives 8 drugs
D09AA Medicated dressings with antiinfectives 11 drugs
P01CC Nitrofuran derivatives 1 drug
S01AX Other antiinfectives 13 drugs
S02AA Antiinfectives 17 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Klebsiella cystitis | indication | 60867007 | |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Staphylococcus Saprophyticus Urinary Tract Infection | indication | ||
| Enterococcus Urinary Tract Infection | indication | ||
| Staphylococcus Aureus Urinary Tract Infection | indication | ||
| Enterobacter Cystitis | indication | ||
| Prevention of Bacterial Urinary Tract Infection | off-label use | ||
| Anuria | contraindication | 2472002 | DOID:2983 |
| Acute hepatitis | contraindication | 37871000 | |
| Vitamin B deficiency | contraindication | 47903000 | |
| Fibrosis of lung | contraindication | 51615001 | DOID:3770 |
| Obstructive hyperbilirubinemia | contraindication | 59848001 | |
| Interstitial pneumonia | contraindication | 64667001 | |
| Optic neuritis | contraindication | 66760008 | DOID:1210 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Chronic hepatitis | contraindication | 76783007 | DOID:2237 |
| Oliguria | contraindication | 83128009 | |
| Cholestatic hepatitis | contraindication | 95556007 | |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
| Cobalamin deficiency | contraindication | 190634004 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Drug-induced hepatitis | contraindication | 235876009 | |
| Peripheral nerve disease | contraindication | 302226006 | |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Surface bacterial infections of wounds | Indication |
| Cats | Surface bacterial infections of burns | Indication |
| Cats | Surface bacterial infections of skin ulcers and abscesses | Indication |
| Dogs | Surface bacterial infections of wounds | Indication |
| Dogs | Surface bacterial infections of burns | Indication |
| Dogs | Surface bacterial infections of skin ulcers and abscesses | Indication |
| Horses | Surface bacterial infections of wounds | Indication |
| Horses | Surface bacterial infections of burns | Indication |
| Horses | Surface bacterial infections of skin ulcers and abscesses | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| NFZ Puffer | Neogen Corp. | 1 |
| Fura Ointment | Farnam Companies Inc. | 1 |
| Fura-Septin Soluble Dressing | Bimeda Animal Health Limited | 1 |
| Nitrofurazone Dressing | Cronus Pharma Specialities India Private Limited | 1 |
| Nitrofurazone Soluble Powder | Cronus Pharma Specialities India Private Limited | 1 |
| Nitrofurazone Ointment | Bimeda Animal Health Limited | 1 |
| Nitrofurazone Anesthetic Dress. | Med-Pharmex Inc. | 2 |
| Fura-Zone | Squire Laboratories Inc. | 1 |
| Nitrofurazone Ointment | Sparhawk Laboratories Inc. | 1 |
| NFZ Wound Dressing | Neogen Corp. | 1 |
| Nitrofurazone Soluble Dressing | Med-Pharmex Inc. | 1 |
| Nitrofurazone Soluble Dressing | First Priority Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.85 | acidic |
| pKa2 | 12.47 | acidic |
| pKa3 | 0.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucose-6-phosphate 1-dehydrogenase | Enzyme | WOMBAT-PK | |||||||
| Sterile alpha and TIR motif-containing protein 1 | Enzyme | IC50 | 4.05 | CHEMBL | |||||
| Snake venom metalloproteinase Bap1 | Enzyme | IC50 | 4.06 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018879 | VUID |
| N0000147174 | NUI |
| D00862 | KEGG_DRUG |
| 4018879 | VANDF |
| C0028157 | UMLSCUI |
| NFZ | PDB_CHEM_ID |
| CHEMBL869 | ChEMBL_ID |
| DB00336 | DRUGBANK_ID |
| D009583 | MESH_DESCRIPTOR_UI |
| 5447130 | PUBCHEM_CID |
| 4160 | INN_ID |
| X8XI70B5Z6 | UNII |
| 227727 | RXNORM |
| 2323 | MMSL |
| 402 | MMSL |
| 5182 | MMSL |
| 002857 | NDDF |
| 332799007 | SNOMEDCT_US |
| 87097009 | SNOMEDCT_US |
| CHEBI:44368 | CHEBI |
| 12366 | IUPHAR_LIGAND_ID |
| X8XI70B5Z6 | INXIGHT DRUGS |
Pharmaceutical products:
None